Abstract
Alzheimer’s disease affects approximately 6% of people over the age of 65 years. It is characterized as chronic degeneration of cortical neurons, with loss of memory, cognition and executive functions. As the disease progresses, it is accompanied by accumulation of amyloid plaques and neurofibrillary tangles in key areas of the brain, leading to a loss of neurogenesis and synaptic plasticity in the hippocampus, along with changes in the levels of essential neurotransmitters such as acetylcholine and glutamate. Individuals with concomitant diseases such as depression, diabetes and cardiovascular disorders have a higher risk of developing Alzheimer’s disease, and those who have a healthier diet and partake in regular exercise and intellectual stimulation have a lower risk of developing the disorder. This chapter describes the advances made in early diagnosis of Alzheimer’s disease as this could help to improve outcomes for the patients by facilitating earlier treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K et al (2008) Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 7:812–826
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9(1):63–75 e62. https://doi.org/10.1016/j.jalz.2012.11.007
https://www.alz.co.uk/research/worldalzheimerreport2016sheet.pdf
Perneczky R (ed) (2018) Biomarkers for preclinical Alzheimer’s disease (Neuromethods), 1st edn. Humana Press, Clifton. ISBN-10: 1493976737
Kazim SF, Iqbal K (2016) Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease. Mol Neurodegener 11(1):50. https://doi.org/10.1186/s13024-016-0119-y
Mu Y, Gage FH (2011) Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener 6:85. https://doi.org/10.1186/1750-1326-6-85
Battaglia F, Wang HY, Ghilardi MF, Gashi E, Quartarone A, Friedman E et al (2007) Cortical plasticity in Alzheimer’s disease in humans and rodents. Biol Psychiatry 62:1405–1412
Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2(8000):1403
Hung SY, Fu WM (2017) Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci 24(1):47. https://doi.org/10.1186/s12929-017-0355-7
Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L et al (2004) Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 140(7):501–509
Guest PC (2017) Biomarkers and mental illness: it’s not all in the mind, 1st edn. Copernicus, Göttingen. ISBN-10: 3319460870
Barron AM, Pike CJ (2012) Sex hormones, aging, and Alzheimer’s disease. Front Biosci (Elite Ed) 4:976–997
McGeer PL, McGeer EG (2001) Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 58(11):1790–1792
van Exel E, Eikelenboom P, Comijs H, Frölich M, Smit JH, Stek ML et al (2009) Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry 66(11):1263–1270
Moustafa AA, Hassan M, Hewedi DH, Hewedi I, Garami JK, Al Ashwal H et al (2018) Genetic underpinnings in Alzheimer’s disease—a review. Rev Neurosci 29(1):21–38
Ford E, Greenslade N, Paudyal P, Bremner S, Smith HE, Banerjee S et al (2018) Predicting dementia from primary care records: a systematic review and meta-analysis. PLoS One 13(3):e0194735. https://doi.org/10.1371/journal.pone.0194735
Friedman DB, Becofsky K, Anderson LA, Bryant LL, Hunter RH, Ivey SL et al (2015) Public perceptions about risk and protective factors for cognitive health and impairment: a review of the literature. Int Psychogeriatr 27(8):1263–1275
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer’s disease. Subcell Biochem 65:329–352
Huse JT, Doms RW (2000) Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer’s disease. Mol Neurobiol 22(1–3):81–98
Rentz DM, Parra Rodriguez MA, Amariglio R, Stern Y, Sperling R, Ferris S (2013) Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review. Alzheimers Res Ther 5:58. https://doi.org/10.1186/alzrt222
Rentz DM, Amariglio RE, Becker JA, Frey M, Olson LE, Frishe K et al (2011) Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia 49(9):2776–2783
Cecchini MA, Yassuda MS, Bahia VS, de Souza LC, Guimarães HC, Caramelli P et al (2017) Recalling feature bindings differentiates Alzheimer’s disease from frontotemporal dementia. J Neurol 264(10):2162–2169
Holden HM, Hoebel C, Loftis K, Gilbert PE (2012) Spatial pattern separation in cognitively normal young and older adults. Hippocampus 22(9):1826–1832
Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ (2017) Biomarkers for the early detection and progression of Alzheimer’s disease. Neurotherapeutics 14(1):35–53
Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S et al (2017) A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer’s disease: the PBT2-204 IMAGINE study. Alzheimers Dement (N Y) 3(4):622–635
Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM et al (2018) Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med 15(1):e1002482. https://doi.org/10.1371/journal.pmed.1002482
Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J et al (2018) Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol Med. 10(5). https://doi.org/10.15252/emmm.201708763
Herman L, Atri A, Salloway S (2017) Alzheimer’s disease in primary care: the significance of early detection, diagnosis, and intervention. Am J Med 130(6):756. https://doi.org/10.1016/j.amjmed.2017.04.001
Wattmo C, Wallin ÅK (2017) Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimers Res Ther 9(1):70. https://doi.org/10.1186/s13195-017-0294-2
http://www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.pdf
Manning FC (1994) Tacrine therapy for the dementia of Alzheimer’s disease. Am Fam Physician 50(4):819–826
Gauthier S, Panisset M, Nalbantoglu J, Poirier J (1997) Alzheimer’s disease: current knowledge, management and research. CMAJ 157(8):1047–1052
Nordberg A, Svensson AL (1998) Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology. Drug Saf 19(6):465–480
Grutzendler J, Morris JC (2001) Cholinesterase inhibitors for Alzheimer’s disease. Drugs 61(1):41–52
Doraiswamy PM (2002) Non-cholinergic strategies for treating and preventing Alzheimer’s disease. CNS Drugs 16(12):811–824
Mezeiova E, Korabecny J, Sepsova V, Hrabinova M, Jost P, Muckova L et al (2017) Development of 2-methoxyhuprine as novel lead for Alzheimer’s disease therapy. Molecules 22(8). https://doi.org/10.3390/molecules22081265
Oset-Gasque MJ, Marco-Contelles J (2017) New tacrines as anti-Alzheimer’s disease agents. The (Benzo)Chromeno-PyranoTacrines. Curr Top Med Chem 17(31):3349–3360
Doggrell S (2003) Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease? Expert Opin Pharmacother 4(10):1857–1860
Modrego PJ (2010) Depression in Alzheimer’s disease. Pathophysiology, diagnosis, and treatment. J Alzheimers Dis 21(4):1077–1087
El Haj M, Gallouj K, Antoine P (2017) Google calendar enhances prospective memory in Alzheimer’s disease: a case report. J Alzheimers Dis 57(1):285–291
Brown EL, Ruggiano N, Li J, Clarke PJ, Kay ES, Hristidis V (2017) Smartphone-based health technologies for dementia care: opportunities, challenges, and current practices. J Appl Gerontol 1:733464817723088. https://doi.org/10.1177/0733464817723088
Brown BM, Peiffer JJ, Sohrabi HR, Mondal A, Gupta VB, Rainey-Smith SR et al (2012) Intense physical activity is associated with cognitive performance in the elderly. Transl Psychiatry 2:e191. https://doi.org/10.1038/tp.2012.118
Huntley JD, Gould RL, Liu K, Smith M, Howard RJ (2015) Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open 5(4):e005247. https://doi.org/10.1136/bmjopen-2014-005247
Jhee S, Shiovitz T, Crawford AW, Cutler NR (2001) Beta-amyloid therapies in Alzheimer’s disease. Expert Opin Investig Drugs 10(4):593–605
Pollack SJ, Lewis H (2005) Secretase inhibitors for Alzheimer’s disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 6(1):35–47
Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38(9):1205–1235
Nisha CM, Kumar A, Nair P, Gupta N, Silakari C, Tripathi T et al (2016) Molecular docking and in silico ADMET study reveals acylguanidine 7a as a potential inhibitor of β-secretase. Adv Bioinforma 2016:9258578. https://doi.org/10.1155/2016/9258578
Galimberti D, Scarpini E (2017) Pioglitazone for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs 26(1):97–101
Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA (2011) Insulin-resistant brain state: the culprit in sporadic Alzheimer’s disease? Ageing Res Rev 10(2):264–273
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32(9):1626–1633
Cheng H, Shang Y, Jiang L, Shi TL, Wang L (2016) The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: a meta-analysis. Int J Neurosci 126(4):299–307
Wisniewski T, Drummond E (2016) Developing therapeutic vaccines against Alzheimer’s disease. Expert Rev Vaccines 15(3):401–415
Grüninger F (2015) Invited review: drug development for tauopathies. Neuropathol Appl Neurobiol 41(1):81–96
Godyń J, Jończyk J, Panek D, Malawska B (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 68(1):127–138
Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R et al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16(2):123–134
Wang C, Shou Y, Pan J, Du Y, Liu C, Wang H (2018) The relationship between cholesterol level and Alzheimer’s disease-associated APP proteolysis/Aβ metabolism. Nutr Neurosci 11:1–11. https://doi.org/10.1080/1028415X.2017.1416942
Schultz BG, Patten DK, Berlau DJ (2018) The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener 7:5. https://doi.org/10.1186/s40035-018-0110-3
Li HH, Lin CL, Huang CN (2018) Neuroprotective effects of statins against amyloid β-induced neurotoxicity. Neural Regen Res 13(2):198–206
Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ et al (2018) Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep 8(1):5804. https://doi.org/10.1038/s41598-018-24248-8
Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ et al (1998) Alzheimer’s disease—synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439–461
Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T et al (2001) Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer’s disease. Brain Res 920:32–40
Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G (2016) Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease. Neurochem Int 95:63–74
Figueiredo-Pereira ME, Corwin C, Babich J (2016) Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration. Ann N Y Acad Sci 1363:125–137
Camargo CHF, Justus FF, Retzlaff G, Blood MRY, Schafranski MD (2015) Action of anti-TNF-α drugs on the progression of Alzheimer’s disease: a case report. Dement Neuropsychol 9(2):196–200
Butchart J, Brook L, Hopkins V, Teeling J, Püntener U, Culliford D et al (2015) Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology 84(21):2161–2168
Mazzanti G, Di Giacomo S (2016) Curcumin and resveratrol in the management of cognitive disorders: what is the clinical evidence?. Molecules 21(9). https://doi.org/10.3390/molecules21091243
Barbara R, Belletti D, Pederzoli F, Masoni M, Keller J, Ballestrazzi A et al (2017) Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates. Int J Pharm 526(1–2):413–424
Liu QP, Wu YF, Cheng HY, Xia T, Ding H, Wang H et al (2016) Habitual coffee consumption and risk of cognitive decline/dementia: a systematic review and meta-analysis of prospective cohort studies. Nutrition 32:628–636
Wu L, Sun D, He Y (2017) Coffee intake and the incident risk of cognitive disorders: a dose-response meta-analysis of nine prospective cohort studies. Clin Nutr 36(3):730–736
Camandola S, Plick N, Mattson MP (2018) Impact of coffee and cacao purine metabolites on neuroplasticity and neurodegenerative disease. Neurochem Res. https://doi.org/10.1007/s11064-018-2492-0
Thaipisuttikul P, Galvin JE (2012) Use of medical foods and nutritional approaches in the treatment of Alzheimer’s disease. Clin Pract (Lond) 9:199–209
Farina N, Rusted J, Tabet N (2014) The effect of exercise interventions on cognitive outcome in Alzheimer’s disease: a systematic review. Int Psychogeriatr 26:9–18
Bertram S, Brixius K, Brinkmann C (2016) Exercise for the diabetic brain: how physical training may help prevent dementia and Alzheimer’s disease in T2DM patients. Endocrine 53(2):350–363
Shankle WR, Hara J, Barrentine LW, Curole MV (2016) CerefolinNAC therapy of hyperhomocysteinemia delays cortical and white matter atrophy in Alzheimer’s disease and cerebrovascular disease. J Alzheimers Dis 54(3):1073–1084
Ohnuma T, Toda A, Kimoto A, Takebayashi Y, Higashiyama R, Tagata Y et al (2016) Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study. Clin Interv Aging 11:29–36
Berti V, Walters M, Sterling J, Quinn CG, Logue M, Andrews R et al (2018) Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology 90(20):e1789–e1798. https://doi.org/10.1212/WNL.0000000000005527
Pedersen BK (2017) Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Investig 47(8):600–611
Zanuso S, Sacchetti M, Sundberg CJ, Orlando G, Benvenuti P, Balducci S (2017) Exercise in type 2 diabetes: genetic, metabolic and neuromuscular adaptations. A review of the evidence. Br J Sports Med 51(21):1533–1538
Rendeiro C, Rhodes JS (2018) A new perspective of the hippocampus in the origin of exercise-brain interactions. Brain Struct Funct 223(6):2527–2545. https://doi.org/10.1007/s00429-018-1665-6
Devenney KE, Sanders ML, Lawlor B, Olde Rikkert MGM, Schneider S, NeuroExercise Study Group (2017) The effects of an extensive exercise programme on the progression of Mild Cognitive Impairment (MCI): study protocol for a randomised controlled trial. BMC Geriatr 17(1):75. https://doi.org/10.1186/s12877-017-0457-9
Karssemeijer EG, Bossers WJ, Aaronson JA, Kessels RP, Olde Rikkert MG (2017) The effect of an interactive cycling training on cognitive functioning in older adults with mild dementia: study protocol for a randomized controlled trial. BMC Geriatr 17(1):73. https://doi.org/10.1186/s12877-017-0464-x
Jensen CS, Portelius E, Høgh P, Wermuth L, Blennow K, Zetterberg H et al (2017) Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer’s disease. Alzheimers Dement (N Y) 3(2):284–290
Barreto PS, Demougeot L, Vellas B, Rolland Y (2017) Exercise training for preventing dementia, mild cognitive impairment, and clinically meaningful cognitive decline: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci 73(11):1504–1511. https://doi.org/10.1093/gerona/glx234
Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K et al (2014) The road ahead to cure Alzheimer’s disease: development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis 1(3):181–202
Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M et al (2018) Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment. Alzheimers Res Ther 10(1):33. https://doi.org/10.1186/s13195-018-0362-2
Tang X, Cai F, Ding DX, Zhang LL, Cai XY, Fang Q (2018) Magnetic resonance imaging relaxation time in Alzheimer’s disease. Brain Res Bull 140:176–189. https://doi.org/10.1016/j.brainresbull.2018.05.004
Matsuda H (2016) MRI morphometry in Alzheimer’s disease. Ageing Res Rev 30:17–24
Tae WS, Ham BJ, Pyun SB, Kang SH, Kim BJ (2018) Current clinical applications of diffusion-tensor imaging in neurological disorders. J Clin Neurol 14(2):129–140
Hua J, Liu P, Kim T, Donahue M, Rane S, Chen JJ et al (2018) MRI techniques to measure arterial and venous cerebral blood volume. Neuroimage. pii: S1053-8119(18)30115-0. https://doi.org/10.1016/j.neuroimage.2018.02.027
Schilling LP, Zimmer ER, Shin M, Leuzy A, Pascoal TA, Benedet AL et al (2016) Imaging Alzheimer’s disease pathophysiology with PET. Dement Neuropsychol 10(2):79–90
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55(3):306–319
Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E et al (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68(3):319–329
Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73(10):754–760
Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brašić JR et al (2013) Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am J Geriatr Psychiatry 21(3):272–278
Fischer FU, Wolf D, Scheurich A, Fellgiebel A (2015) Alzheimer’s disease neuroimaging I. Altered whole-brain white matter networks in preclinical Alzheimer’s disease. Neuroimage Clin 8:660–666
Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A et al (2015) [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer’s disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 11(8):975–985
Chiaravalloti A, Castellano AE, Ricci M, Barbagallo G, Sannino P, Ursini F et al (2018) Coupled imaging with [18F]FBB and [18F]FDG in AD subjects show a selective association between amyloid burden and cortical dysfunction in the brain. Mol Imaging Biol 20(4):659–666
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM et al (2000) Inflammation and Alzheimer’s disease. Neurol Aging 21(3):383–421
Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE et al (2001) In-vivo measurement of activated microglia in dementia. Lancet 358(9280):461–457
Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Långström B et al (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nuclear Med 53(1):37–46
Rodriguez-Vieitez E, Nordberg A (2018) Imaging neuroinflammation: quantification of astrocytosis in a multitracer PET approach. Methods Mol Biol 1750:231–251
Sebastián-Serrano Á, de Diego-García L, Díaz-Hernández M (2018) The neurotoxic role of extracellular Tau protein. Int J Mol Sci 19(4). https://doi.org/10.3390/ijms19040998
Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P (2014) Developments in Tau PET imaging. Can J Neurol Sci 41(5):547–553
Shimada H, Kitamura S, Shinotoh H, Endo H, Niwa F, Hirano S et al (2016) Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer’s disease spectrum brains: a [<sup>11</sup>C]PBB3-PET study. Alzheimers Dement (Amst) 6:11–20
Ishiki A, Okamura N, Furukawa K, Furumoto S, Harada R, Tomita N et al (2015) Longitudinal assessment of Tau pathology in patients with Alzheimer’s disease using [18F]THK-5117 positron emission tomography. PLoS One 10(10):e0140311. https://doi.org/10.1371/journal.pone.0140311
Schaffer C, Sarad N, DeCrumpe A, Goswami D, Herrmann S, Morales J et al (2015) Biomarkers in the diagnosis and prognosis of Alzheimer’s disease. J Lab Autom 20(5):589–600
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42(1):85–94
Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA et al (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and longterm outcome. JAMA 286(17):2120–2127
Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32(4):486–510
Scholl M, Damian A, Engler H (2014) Fluorodeoxyglucose PET in neurology and psychiatry. PET Clin 9(4):371–390
Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y et al (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging 36(5):811–822
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234
Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L et al (2007) Prediction of Alzheimer’s disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23:316–320
Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H et al (2007) Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 101:1053–1059
Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P et al (2017) Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis 55:813–822
Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL et al (2015) Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther 7(1):30. https://doi.org/10.1186/s13195-015-0114-5
De Roeck EE, Engelborghs S, Dierckx E (2016) Next generation brain health depends on early Alzheimer disease diagnosis: from a timely diagnosis to future population screening. J Am Med Dir Assoc 17(5):452–453
Vos SJB, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W et al (2015) Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain 138:1327–1338
Bjerke M, Zetterberg H, Edman Å, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis 27(3):665–676
Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP et al (2013) Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36(4):759–767
Llorens F, Schmitz M, Ferrer I, Zerr I (2016) CSF biomarkers in neurodegenerative and vascular dementias. Prog Neurobiol 138-140:36–53
Blennow K, Zetterberg H (2018) The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis 62(3):1125–1140
Brinkmalm A, Brinkmalm G, Honer WG, Frolich L, Hausner L, Minthon L et al (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Mol Neurodegener 9:53. https://doi.org/10.1186/1750-1326-9-53
Ohrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H et al (2016) The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease. Alzheimers Res Ther 8:41. https://doi.org/10.1186/s13195-016-0208-8
Blennow K (2017) A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther 6(Suppl 1):15–24
Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M (2009) Identifying early markers of Alzheimer’s disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 1180:56–67
Perneczky R, Guo LH (2016) Plasma proteomics biomarkers in Alzheimer’s disease: latest advances and challenges. Methods Mol Biol 1303:521–529
Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S (2009) No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 55(8):820–825
Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J (2018) Multiplex immunoassay measurement of amyloid-β<sub>42</sub> to amyloid-β<sub>40</sub> ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease. Exp Brain Res 236(5):1241–1250
Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ et al (2018) Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. pii: S1552-5260(18)30067-0. https://doi.org/10.1016/j.jalz.2018.02.013
Neergaard JS, Dragsbæk K, Christiansen C, Karsdal MA, Brix S, Henriksen K (2018) Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: a prospective study. PLoS One 13(4):e0194802. https://doi.org/10.1371/journal.pone.0194802
O’Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM et al (2011) A blood-based algorithm for the detection of Alzheimer’s disease. Dement Geriatr Cogn Disord 32(1):55–62
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R et al (2014) Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 10(6):799–807
Choi HJ, Byun MS, Yi D, Sohn BK, Lee JH, Lee JY et al (2017) Associations of thyroid hormone serum levels with in-vivo Alzheimer’s disease pathologies. Alzheimers Res Ther 9(1):64. https://doi.org/10.1186/s13195-017-0291-5
Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K et al (2017) Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89(21):2167–2175
Cao X, Zhu M, He Y, Chu W, Du Y, Du H (2018) Increased serum acylated ghrelin levels in patients with mild cognitive impairment. J Alzheimers Dis 61(2):545–552
Ouma S, Suenaga M, Bölükbaşı Hatip FF, Hatip-Al-Khatib I, Tsuboi Y et al (2018) Serum vitamin D in patients with mild cognitive impairment and Alzheimer’s disease. Brain Behav 8(3):e00936. https://doi.org/10.1002/brb3.936
Guo R, Fan G, Zhang J, Wu C, Du Y, Ye H et al (2017) A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer’s disease. J Alzheimers Dis 60(4):1365–1377
Wei H, Xu Y, Xu W, Zhou Q, Chen Q, Yang M et al (2018) Serum exosomal miR-223 serves as a potential diagnostic and prognostic biomarker for dementia. Neuroscience 379:167–176
Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC (2018) The serum exosome derived MicroRNA-135a, -193b, and -384 were potential Alzheimer’s disease biomarkers. Biomed Environ Sci 31(2):87–89
Denk J, Oberhauser F, Kornhuber J, Wiltfang J, Fassbender K, Schroeter ML et al (2018) Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS One 13(5):e0197329. https://doi.org/10.1371/journal.pone.0197329
Wu Y, Xu J, Xu J, Cheng J, Jiao D, Zhou C et al (2017) Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer’s disease. Tohoku J Exp Med 242(2):129–136
Magalhães TNC, Weiler M, Teixeira CVL, Hayata T, Moraes AS, Boldrini VO et al (2017) Systemic inflammation and multimodal biomarkers in amnestic mild cognitive impairment and Alzheimer’s disease. Mol Neurobiol 55(7):5689–5697. https://doi.org/10.1007/s12035-017-0795-9
Lai KSP, Liu CS, Rau A, Lanctôt KL, Köhler CA, Pakosh M et al (2017) Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry 88(10):876–882
Chen A, Oakley AE, Monteiro M, Tuomela K, Allan LM, Mukaetova-Ladinska EB et al (2016) Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Neurobiol Aging 38:56–67. https://doi.org/10.1016/j.neurobiolaging.2015.10.021
Choi C, Jeong JH, Jang JS, Choi K, Lee J, Kwon J et al (2008) Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer’s disease by color-coded bead technology. J Clin Neurol 4(2):84–88. https://doi.org/10.3988/jcn.2008.4.2.84
Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J et al (2015) Central nervous system and peripheral inflammatory processes in Alzheimer’s disease: biomarker profiling approach. Front Neurol 6:181. https://doi.org/10.3389/fneur.2015.00181
Hochstrasser T, Marksteiner J, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C (2011) Two blood monocytic biomarkers (CCL15 and p21) combined with the mini-mental state examination discriminate Alzheimer’s disease patients from healthy subjects. Dement Geriatr Cogn Dis Extra 1(1):297–309
Doustar J, Torbati T, Black KL, Koronyo Y, Koronyo-Hamaoui M (2017) Optical coherence tomography in Alzheimer’s disease and other neurodegenerative diseases. Front Neurol 8:701. https://doi.org/10.3389/fneur.2017.00701
Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M (2016) Ocular indicators of Alzheimer’s: exploring disease in the retina. Acta Neuropathol 132:767–787
Coppola G, Di Renzo A, Ziccardi L, Martelli F, Fadda A, Manni G et al (2015) Optical coherence tomography in Alzheimer’s disease: a meta-analysis. PLoS One 10:e0134750. https://doi.org/10.1371/journal.pone.0134750
Schumacher S, Nestler J, Otto T, Wegener M, Ehrentreich-Förster E, Michel D et al (2012) Highly-integrated lab-on-chip system for point-of-care multiparameter analysis. Lab Chip 12:464–473
Peter H, Wienke J, Bier FF (2017) Lab-on-a-Chip multiplex assays. Methods Mol Biol 1546:283–294
Peter H, Wienke J, Guest PC, Bistolas N, Bier FF (2017) Lab-on-a-Chip proteomic assays for psychiatric disorders. Adv Exp Med Biol 974:339–349
Peter H, Bistolas N, Schumacher S, Laurisch C, Guest PC, Höller U et al (2018) Lab-on-a-Chip device for rapid measurement of vitamin D levels. Methods Mol Biol 1735:477–486
Yetisen AK, Martinez-Hurtado JL, da Cruz VF, Simsekler MC, Akram MS, Lowe CR (2014) The regulation of mobile medical applications. Lab Chip 14:833–840
Martinez-Hurtado JL, Yetisen AK, Yun SH (2017) Multiplex smartphone diagnostics. Methods Mol Biol 1546:295–302
Matías-García PR, Martinez-Hurtado JL (2018) Kidney smartphone diagnostics. Methods Mol Biol 1735:487–498
Vegt J, Guest PC (2018) A user-friendly app for blood coagulation disorders. Methods Mol Biol 1735:499–504
Matías-García PR, Martinez-Hurtado JL, Beckley A, Schmidmayr M, Seifert-Klauss V (2018) Hormonal smartphone diagnostics. Methods Mol Biol 1735:505–515
Hartin PJ, Nugent CD, McClean SI, Cleland I, Tschanz JT, Clark CJ et al (2016) The empowering role of mobile apps in behavior change interventions: the gray matters randomized controlled trial. JMIR Mhealth Uhealth 4(3):e93. https://doi.org/10.2196/mhealth.4878
Bonn SE, Alexandrou C, Hjörleifsdottir Steiner K, Wiklander K, Östenson CG, Löf M (2018) App-technology to increase physical activity among patients with diabetes type 2—the DiaCert-study, a randomized controlled trial. BMC Public Health 18(1):119. https://doi.org/10.1186/s12889-018-5026-4
Krishna S, Boren SA, Balas EA (2009) Healthcare via cell phones: a systematic review. Telemed J E Health 15:231–240
Guo T, Patnaik R, Kuhlmann K, Rai AJ, Sia SK (2015) Smartphone dongle for simultaneous measurement of hemoglobin concentration and detection of HIV antibodies. Lab Chip 15:3514–3520
Barbosa AI, Gehlot P, Sidapra K, Edwards AD, Reis NM (2015) Portable smartphone quantitation of prostate specific antigen (PSA) in a fluoropolymer microfluidic device. Biosens Bioelectron 70:5–14
Liao SC, Peng J, Mauk MG, Awasthi S, Song J, Friedman H (2016) Smart cup: a minimally-instrumented, smartphone-based point-of-care molecular diagnostic device. Sens Actuators B Chem 229:232–238
Yeo SJ, Choi K, Cuc BT, Hong NN, Bao DT, Ngoc NM et al (2016) Smartphone-based fluorescent diagnostic system for highly pathogenic H5N1 viruses. Theranostics 6:231–242
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Guest, F.L. (2019). Early Detection and Treatment of Patients with Alzheimer’s Disease: Future Perspectives. In: Guest, P. (eds) Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology(), vol 1118. Springer, Cham. https://doi.org/10.1007/978-3-030-05542-4_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-05542-4_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-05541-7
Online ISBN: 978-3-030-05542-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)